The possible occurrence of an actual relationship in tissues between FZD10 or ERK/p-ERK1/2 and the clinicopathological factor Ki-67 is a key issue that needs to be closely assessed to understand the role of these tumor-activated proteins in CRC and GC patients. This evidence concerns the gene MAPK3 and colorectal carcinoma.